
Danish biotech company Rhovac, spearheaded by Anders Månsson, former executive of Leo Pharma and Ferring Pharmaceuticals, has made it its goal to examine the opportunities of either striking a deal or entering a partnership pertaining to its lead candidate RV001, the company reports in a press relase on Monday.
RV001, which is a RhoC based cancer vaccine, was granted the Fast Track Designation by the US Food and Drug Administration (FDA) last year.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app